Evidence map›Paper›PMID 28965100›Full record

Trial reportBMJ open2017

Evolution of pain at 3 months by oral resveratrol in knee osteoarthritis (ARTHROL): protocol for a multicentre randomised double-blind placebo-controlled trial.

Christelle Nguyen, Isabelle Boutron, Gabriel Baron, Emmanuel Coudeyre, Francis Berenbaum, Serge Poiraudeau, François Rannou

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02905799 (Evolution of Pain at Three Months by Oral Resveratrol in Primary Knee Osteoarthritis), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02905799 phase3completednot on this map

Evolution of Pain at Three Months by Oral Resveratrol in Primary Knee Osteoarthritis: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2017 to 2022Enrolled142ConditionsKnee OsteoarthritisArmsoral resveratrol, oral placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Mitochondria and sensory processing in inflammatory and neuropathic pain.Frontiers in pain research (Lausanne, Switzerland) · 2022
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Christelle NguyenFaculté de Médecine, Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
Isabelle BoutronFaculté de Médecine, Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
Gabriel BaronFaculté de Médecine, Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
Emmanuel CoudeyreService de Médecine Physique et de Réadaptation, Centre Hospitalo-Universitaire de Clermont-Ferrand, INRA, Université Clermont Auvergne, Clermont-Ferrand, France.
Francis BerenbaumUniversité Paris Pierre et Marie-Curie, Sorbonne Paris Cité, Paris, France.
Serge PoiraudeauFaculté de Médecine, Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
François RannouFaculté de Médecine, Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
Université Paris Cité · FRDélégation Paris 5 · FRHôpital Saint-Antoine · FRUniversité Clermont Auvergne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOsteoarthritis (OA) pathophysiology is driven in part by joint inflammation. Resveratrol has in vitro anti-inflammatory properties. We aim to assess the efficacy of oral resveratrol for knee pain at 3 months in people with knee OA. METHODS AND ANALYSIS: We will conduct a randomised double-blind placebo-controlled trial. Overall, 164 individuals with knee OA fulfilling 1986 American College of Rheumatology criteria will be recruited in three tertiary care centres in France and randomised to receive oral resveratrol, 40 mg (two caplets) two times per day for 1 week, then 20 mg (one caplet) two times per day or a matching placebo for a total of 6 months. Randomisation will be centralised and stratified by centre. The allocation ratio of assignments will be 1:1. The primary outcome will be the mean change from baseline in knee pain on a self-administered 11-point pain Numeric Rating Scale at 3 months. Secondary outcomes will be the mean change in knee pain at 6 months, the function subscore of the Western Ontario and McMaster Universities Arthritis Index score, patient global assessment, proportion of responders according to the Osteoarthritis Research Society International-Outcome Measures in Rheumatology criteria at 3 and 6 months, and self-reported number of intra-articular injections of corticosteroids or hyaluronic acid and consumption of analgesics and non-steroidal anti-inflammatory drugs since the last contact. Other interventions will be allowed and self-reported. Adherence will be monitored by capsule counts and a booklet and adverse events recorded at 3 and 6 months. Statisticians, treating physicians and participants will be blinded to the allocated treatment. ETHICS AND DISSEMINATION: The oral resveratrol in knee osteoarthritis (ARTHROL) trial has been authorised by the TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT02905799. Pre-results. First received: 14 September 2016. Last updated: 16 September 2016. Status: not yet recruiting.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodFranceHumansKnee JointOsteoarthritis, KneePainPain MeasurementProspective StudiesResearch DesignResveratrolStilbenesTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalResveratrolStilbenesclinical trial.kneeoral treatmentOsteoarthritispainresveratrol

Identifiers

PMID28965100
PMCPMC5640106
OpenAlexW2756875431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.